Decibel Therapeutics taps 4G Clinical for RTSM support

hearing ear
Decibel Therapeutics, which focuses on therapies for hearing and balance disorders, taps 46 Clinical to provide randomization and trial supply management. (Pixabay/tung256)

Decibel Therapeutics, which focuses on therapies for hearing and balance disorders, has tapped 4G Clinical to provide randomization and trial supply management.

4G will, specifically, provide IxRS/RTSM support. Financial terms of the deal weren’t disclosed.

RTSM systems support the randomization of patients into different arms of a trial and the supply of study drugs to sites. The technology has evolved from the phone-based systems of the 1990s, known by the abbreviation IVRS, to the web-based platforms in use today.

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

“The complexity of today’s trials requires an RTSM solution that is flexible enough to adapt as trials evolve,” Heather Wolff, a senior director at Decibel, said in a statement. “4G Clinical’s modern technology is best-in-class and the tool that will be the best fit for an emerging biotech company such as Decibel.”

4G’s chief executive, David Kelleher, said in the announcement that as biotechs make critical advancements in science, the company will remain focused on making “it easier for them to let the science take the lead in their trials.”

Medidata and Paraxel are 4G’s main competition in the market.

Suggested Articles

WIRB-Copernicus Group has added two new executives to its roster as it expands its Global Research Network of investigative sites.

Incoming FDA Commissioner Ned Sharpless used his first official talk to ensure we all know he’s not looking to tear up Scott Gottlieb’s legacy.

Charles River Labs and the CHDI Foundation have signed a five-year extension for their Huntington’s disease work.